Arrowhead Pharmaceuticals Stock Forecast, Price & News

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals or view top-rated stocks.

How has Arrowhead Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 78.0% and is now trading at $50.84.
View which stocks have been most impacted by COVID-19.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Arrowhead Pharmaceuticals.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings results on Monday, November, 22nd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.65. The biotechnology company had revenue of $38.28 million for the quarter, compared to analysts' expectations of $79.31 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 32.27% and a negative net margin of 101.85%. During the same quarter in the prior year, the firm posted ($0.48) earnings per share.
View Arrowhead Pharmaceuticals' earnings history.

What price target have analysts set for ARWR?

6 equities research analysts have issued 12 month price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $45.00 to $110.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $90.67 in the next twelve months. This suggests a possible upside of 78.3% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:

• Christopher Richard Anzalone, President, Chief Executive Officer & Director
• Kenneth Allen Myszkowski, Chief Financial Officer
• Javier San Martin, Chief Medical Officer
• Jeff Ketelhut, Vice President-Information Technology & Systems
• Caroline LaPlaca Davis, Vice President-Clinical Operations

Who are some of Arrowhead Pharmaceuticals' key competitors?

Some companies that are related to Arrowhead Pharmaceuticals include Shiseido (SSDOY), UCB (UCBJF), Horizon Therapeutics Public (HZNP), Viatris (VTRS), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ) and Grifols (GRFS).
View all of ARWR's competitors.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.32%), Russell Investments Group Ltd. (0.20%), Nordea Investment Management AB (0.10%), Louisiana State Employees Retirement System (0.03%), Exchange Traded Concepts LLC (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, State of Alaska Department of Revenue, Vigilare Wealth Management, Stratos Wealth Partners LTD., and Nordea Investment Management AB. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Atlantic Private Wealth LLC, Retirement Systems of Alabama, Lindbrook Capital LLC, Crossmark Global Holdings Inc., Parallel Advisors LLC, MBE Wealth Management LLC, and Louisiana State Employees Retirement System. Company insiders that have bought Arrowhead Pharmaceuticals stock in the last two years include Backer Marianne De, and Douglas B Given.
View insider buying and selling activity for Arrowhead Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $50.84.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $5.30 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140.85 million in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at (626) 304-3400, via email at [email protected], or via fax at 626-304-3401.